David J Yvars Group Abb Vie Inc. Transaction History

David J Yvars Group

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 17, 2023	SELL	$138.31 - $165.87 $324,475 - $389,131	-2,346 Reduced 6.23%	35,325 $0
Q3 2022 Oct 26, 2022	SELL	$134.21 - $153.93 $112,870 - $129,455	-841 Reduced 2.18%	37,671 $5.06 Million
Q2 2022 Jul 15, 2022	SELL	$137.62 - $174.96 $234,366 - $297,956	-1,703 Reduced 4.23%	38,512 $5.92 Million
Q1 2022 Apr 21, 2022	BUY	$131.98 - $163.75 $5.31 Million - $6.59 Million	40,215 New	40,215 $6.52 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of David J Yvars Group, based on Form 13F filings with the SEC.

Stay updated on David J Yvars Group with notifications on news.